The healthcare industry is rapidly transitioning toward data-driven, patient-centric care, with digital biomarkers emerging as one of the most transformative innovations in clinical research and disease management. By leveraging wearable devices, smartphones, medical sensors, artificial intelligence (AI), and cloud-based analytics, digital biomarkers provide continuous, objective, and real-time insights into patient health that were previously difficult to capture through conventional clinical assessments.
The global digital biomarkers market is projected to grow from USD 7.41 billion in 2026 to USD 17.73 billion by 2031, registering an impressive CAGR of 19.1% during the forecast period. The market’s rapid expansion is fueled by the increasing adoption of decentralized clinical trials, AI-powered analytics, remote patient monitoring, and the growing demand for real-world evidence across pharmaceutical and biotechnology industries.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=7725399
Digital Biomarkers Are Transforming Clinical Research
Traditional clinical trials have long relied on periodic hospital visits and manual patient assessments, often providing only limited snapshots of a patient’s health. Digital biomarkers are changing this model by enabling continuous monitoring through wearable sensors, mobile applications, connected medical devices, and digital health platforms.
These technologies capture objective physiological, behavioral, and cognitive data, allowing researchers to monitor patients remotely while generating more comprehensive clinical insights. The shift toward decentralized clinical trials has made digital biomarkers increasingly valuable for improving patient engagement, reducing study costs, and enhancing data quality.
According to data from ClinicalTrials.gov, pharmaceutical and biotechnology companies continue to sponsor a substantial proportion of global clinical trials. More than 130 pharmaceutical and biotechnology organizations have already implemented AI-powered digital biomarkers and sensor-based technologies, with over 1,300 digital endpoints analyzed across clinical studies. Notably, more than 25% of these digital endpoints are now being used as primary clinical endpoints, highlighting the industry’s growing confidence in digitally generated evidence.
Artificial Intelligence Enhances Biomarker Analytics
Artificial intelligence has become a cornerstone of digital biomarker development. AI algorithms analyze large volumes of continuous patient data collected from wearable devices, smartphones, imaging platforms, and remote monitoring systems to identify clinically meaningful patterns.
Machine learning models can detect subtle physiological changes, predict disease progression, assess treatment effectiveness, and generate personalized health insights. These capabilities improve decision-making for both clinicians and pharmaceutical researchers while enabling earlier intervention for patients.
AI-powered analytics also support automated endpoint generation, helping researchers efficiently process complex datasets while ensuring greater consistency and regulatory compliance throughout clinical studies.
Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=7725399
Remote Patient Monitoring Expands Healthcare Access
Remote patient monitoring has become one of the fastest-growing applications of digital biomarkers. Patients can now participate in clinical research without frequent hospital visits, improving convenience while increasing participation from geographically diverse populations.
Continuous monitoring enables healthcare providers to track vital signs, cardiac activity, neurological function, physical movement, sleep patterns, cognitive performance, and behavioral changes in real-world settings. This provides a more accurate representation of patient health than traditional site-based assessments.
The increasing adoption of wearable technologies, connected medical devices, and cloud-based healthcare platforms continues to accelerate demand for digital biomarker solutions across clinical research and routine patient care.
Broad Applications Across Multiple Therapeutic Areas
Digital biomarkers are finding applications across numerous therapeutic disciplines.
Neurology remains one of the largest application areas, where digital biomarkers help monitor Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, and cognitive impairment. Cardiology benefits from continuous ECG monitoring and remote detection of arrhythmias, while behavioral and mental health applications utilize digital assessments to evaluate mood disorders, depression, anxiety, and cognitive performance.
Oncology, respiratory medicine, metabolic diseases, and rare disorders are also increasingly incorporating digital biomarkers into clinical development programs to improve patient monitoring and therapeutic evaluation.
As precision medicine continues to evolve, digital biomarkers are expected to become integral components of personalized healthcare strategies.
Leading Companies Driving Innovation
Several innovative companies are actively shaping the digital biomarkers landscape through advanced software platforms, AI technologies, and strategic partnerships.
IXICO PLC specializes in digital biomarker analytics for neurodegenerative diseases. Its advanced neuroimaging software extracts quantitative biomarkers from imaging and clinical datasets, helping pharmaceutical companies improve clinical trial efficiency and evaluate disease progression. In July 2025, IXICO partnered with the Global Alzheimer’s Platform Foundation to support the Bio-Hermes-002 study, further strengthening digital biomarker adoption in Alzheimer’s disease research.
Ametris, LLC provides comprehensive software platforms that collect, integrate, and analyze digital biomarker data for decentralized clinical trials. In February 2026, the company entered a strategic partnership with AliveCor, Inc. to integrate medical-grade ECG monitoring into its platform. The collaboration enables remote collection of ECG and QT interval data while supporting digital cardiac endpoints for clinical research.
Empatica, Inc. is recognized for its AI-driven neurological and physiological monitoring platforms that continuously generate clinically validated digital endpoints. In October 2025, Empatica expanded its neurological monitoring capabilities through the acquisition of PKG Health, a UK-based developer of wearable technologies for Parkinson’s disease. The acquisition strengthened Empatica’s portfolio of movement analytics and digital biomarkers for neurodegenerative disorders.
Other important companies contributing to market growth include CONNEQT Health, VivoSense, BioSensics, Lunit, Akili, Quibim, Clario, Proscia, Koneksa Health, and Linus Health.
Competitive Landscape
The digital biomarkers market features a dynamic mix of specialized digital health companies, software developers, AI innovators, and clinical research technology providers.
Leading organizations such as IXICO PLC, Ametris, Empatica, AliveCor, and CONNEQT Health are advancing comprehensive platforms that integrate AI-powered analytics, remote patient monitoring, neurocognitive assessments, imaging biomarkers, and cardiac monitoring into clinical research workflows.
Meanwhile, companies including VivoSense, BioSensics, Lunit, Akili, Quibim, Clario, Proscia, Koneksa Health, and Linus Health are expanding disease-specific digital biomarker applications across neurology, cardiology, behavioral health, oncology, and precision diagnostics. Their specialized software platforms continue to strengthen the broader digital biomarker ecosystem while accelerating the adoption of data-driven healthcare.
Future Outlook
The future of the digital biomarkers market is exceptionally promising as healthcare increasingly embraces artificial intelligence, wearable technologies, and decentralized clinical research. Pharmaceutical sponsors are expected to expand the use of digital endpoints to improve clinical trial efficiency, patient engagement, and regulatory decision-making.
As demand for real-world evidence, personalized medicine, and continuous patient monitoring continues to grow, digital biomarkers will become an essential component of modern healthcare delivery. Ongoing advances in AI, sensor technologies, cloud computing, and digital therapeutics will further enhance the accuracy, scalability, and clinical value of digital biomarker platforms, positioning the market for sustained double-digit growth through 2031.
Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=7725399
